MDT:NYE-Medtronic PLC (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 90.07

Change

0.00 (0.00)%

Market Cap

USD 118.35B

Volume

5.05M

Analyst Target

USD 115.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 205.71B
STE STERIS plc

N/A

USD 21.88B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.28B
SNN Smith & Nephew SNATS Inc

N/A

USD 12.71B
BIO Bio-Rad Laboratories Inc

N/A

USD 10.14B
GMED Globus Medical

N/A

USD 10.01B
PEN Penumbra Inc

N/A

USD 7.95B
GKOS Glaukos Corp

N/A

USD 7.18B
INSP Inspire Medical Systems Inc

N/A

USD 5.82B
ITGR Integer Holdings Corp

N/A

USD 4.24B

ETFs Containing MDT

CIB0:XETRA VanEck Bionic Engineering.. 9.77 % 0.00 %

N/A

USD 4.90M
CYBG:LSE VanEck Bionic Engineering.. 9.75 % 0.00 %

N/A

N/A
UMDV:SW iShares US Medical Device.. 9.28 % 0.00 %

N/A

N/A
FLV American Century ETF Trus.. 5.39 % 0.00 %

N/A

N/A
PCIG Litman Gregory Funds Trus.. 5.31 % 0.00 %

N/A

USD 0.03B
FHI:CA CI Health Care Giants Cov.. 5.04 % 0.75 %

N/A

CAD 0.08B
CAMX Cambiar Aggressive Value .. 4.42 % 0.00 %

N/A

USD 0.06B
XUKS:LSE db x-trackers FTSE 100 Sh.. 4.27 % 0.00 %

N/A

USD 7.43M
DIVP The Advisors’ Inner .. 4.05 % 0.00 %

N/A

USD 0.01B
AIVL WisdomTree Trust - Wisdom.. 3.52 % 0.00 %

N/A

USD 0.40B
AGNG Global X Aging Population.. 3.00 % 0.00 %

N/A

USD 0.06B
DXQ:CA Dynamic Active Enhanced Y.. 2.53 % 0.00 %

N/A

N/A
GDVD 2.46 % 0.00 %

N/A

N/A
VSDA VictoryShares Dividend Ac.. 2.35 % 0.35 %

N/A

USD 0.26B
DVND Touchstone ETF Trust - To.. 2.15 % 0.00 %

N/A

USD 0.04B
QUVU 2.01 % 0.00 %

N/A

N/A
PUD.B:CA 1.85 % 0.66 %

N/A

N/A
UDVD:LSE SPDR® S&P US Dividend Ar.. 1.69 % 0.00 %

N/A

USD 3.76B
USDV:LSE SPDR S&P US Dividend Aris.. 1.69 % 0.00 %

N/A

USD 3.85B
USDV:SW SPDR® S&P US Dividend Ar.. 1.69 % 0.00 %

N/A

USD 3.90B
TWAR 1.11 % 0.00 %

N/A

N/A
JIGB 0.45 % 0.14 %

N/A

N/A
VCLT Vanguard Long-Term Corpor.. 0.08 % 0.07 %

N/A

USD 14.56B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

N/A

USD 35.54B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

N/A

USD 8.38B
BLV Vanguard Long-Term Bond I.. 0.00 % 0.07 %

N/A

N/A
CUD:CA iShares US Dividend Growe.. 0.00 % 0.66 %

N/A

CAD 0.35B
DTN 0.00 % 0.38 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

N/A
JDIV J.P. Morgan Exchange-Trad.. 0.00 % 0.12 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
INAU 0.00 % 0.00 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

N/A

CAD 0.05B
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
YLD Principal Active High Yie.. 0.00 % 0.65 %

N/A

USD 0.24B
SPYD:XETRA SPDR® S&P US Dividend Ar.. 0.00 % 0.00 %

N/A

USD 3.76B
SPPD:XETRA SPDR® S&P US Dividend Ar.. 0.00 % 0.00 %

N/A

USD 0.13B
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
REVS Columbia Research Enhance.. 0.00 % 0.00 %

N/A

USD 0.07B
ABEQ Absolute Core Strategy ET.. 0.00 % 0.00 %

N/A

USD 0.09B
FLSP Franklin Liberty Systemat.. 0.00 % 0.00 %

N/A

USD 0.21B
DIVZ Listed Funds Trust - True.. 0.00 % 0.00 %

N/A

USD 0.13B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

CAD 0.09B
SPPD:F SSGA SPDR ETFs Europe I p.. 0.00 % 0.00 %

N/A

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.33% 70% C- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.33% 70% C- 61% D-
Trailing 12 Months  
Capital Gain 24.13% 70% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.13% 70% C- 69% C-
Trailing 5 Years  
Capital Gain -14.65% 61% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.65% 61% D- 38% F
Average Annual (5 Year Horizon)  
Capital Gain -3.22% 32% F 20% F
Dividend Return -0.73% 35% F 19% F
Total Return 2.49% 100% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 19.44% 94% A 55% F
Risk Adjusted Return -3.76% 32% F 21% F
Market Capitalization 118.35B 96% N/A 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.